Novel Health Information Technology Tool Use by Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: Longitudinal Quantitative and Qualitative Patient-Reported Outcomes

INTRODUCTION

Hematopoietic cell transplantation (HCT), commonly referred to as blood and marrow transplantation (BMT), is a complex procedure wherein patients accept significant risks in return for the possibility of cure. These risks are not time limited or static, but instead are variable in course and severity. Given this, HCT patients face numerous mental, physical, and emotional challenges across the HCT trajectory and represent one of the most critically ill cancer populations. The best model of care for such medically complex, and often chronically ill patients, is one that supports patient-centered health care by integrating the use of patient-reported outcomes (PROs). Moreover, patients who are well informed and engaged with their care experience have improved health and psychosocial outcomes. Despite this knowledge, strategies to assess the utility of PROs in clinical practice remain...
METHODS

Procedures

This study was approved by the University of Michigan Institutional Review Board (no. HUM00107014) and registered on ClinicalTrials.gov (identifier NCT03161665). Twenty consecutive allogeneic HCT transplant candidates were recruited by HCT registered nurse coordinators and physicians during the pretransplant work-up stage in the ambulatory care setting before admission to the inpatient HCT unit. All 20 recruited participants met the following eligibility criteria: age ≥ 21 years, first allogeneic HCT, English proficiency, willingness and ability to provide informed consent, and willingness to adhere to study procedures and reporting requirements. After informed consent was obtained, a research coordinator provided a one-on-one, live demo tutorial on use of the tool. Participants were instructed to use the device freely throughout their hospital stay.

PROs

Having met our primary objective of establishing the feasibility of participant enrollment per the a priori design of the study, we report herein on longitudinally collected, quantitative PROs measured at three time points: admission (baseline), discharge, and day 100 post-HCT. Day 100 post-HCT is considered an important turning point or milestone, reflecting a major transition to recovery following a vulnerable period of intense adverse effects from the procedure itself. The PROs included usefulness (Perceived Usefulness),19 ease of use (Perceived Ease of Use),19 activation (Patient Activation Measure),20,21 depression (depression subscale on Profile of Mood States),19 anxiety (State Trait Anxiety Inventory),23 overall distress (Profile of Mood States total score),22 distress related to transplant (Impact of Events Scale-Revised),24 and cancer-related distress (Cancer and Treatment Distress).25 Psychometric properties of the PROs are listed in Table 1.

Data Analysis

Quantitative data. PROs were administered electronically on an Apple iPad tablet using the Qualtrics application, which is a secure online Health Insurance Portability and Accountability Act–compliant platform for administering surveys (www.Qualtrics.com). Time stamps of BMT Roadmap log-in and usage were automatically recorded. Statistical analyses were conducted using Statistical Package for Social Sciences (SPSS) Version 24.26 Demographic data and clinical characteristics of the study were calculated.
| PRO                  | Description                                                                 | Scoring                                                                 | Psychometric Properties                                                                 | High Scores                                                                 |
|----------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| **Usefulness**       |                                                                             |                                                                          |                                                                                         |                                                                             |
| Perceived Usefulness | Six-item scale assessing the degree to which a person believes a particular system would enhance their job performance. | Seven-point Likert scale ranging from 1 = extremely likely to 7 = extremely unlikely. Total score is created by summing the item scores. Totals range from 6 to 42. | Cronbach’s $\alpha = .92$ to .98; good convergent validity ($r = .63$ to .85). | More desirable, reflecting greater usefulness.                               |
| **Usability**        |                                                                             |                                                                          |                                                                                         |                                                                             |
| Perceived Ease of Use| Six-item scale assessing the degree to which a person believes that using a particular system would be free of effort. | Seven-point Likert scale ranging from 1 = extremely likely to 7 = extremely unlikely. Total score is created by summing the item scores. Totals range from 6 to 42. | Cronbach’s $\alpha = .94$; acceptable convergent validity ($r = .45$ to .59). | More desirable, reflecting greater ease of use.                              |
| **Activation**       |                                                                             |                                                                          |                                                                                         |                                                                             |
| Patient Activation Measure (PAM) | Thirteen-item measure that assesses the patient's skills, knowledge, and confidence for self-management. | Four-point Likert scale ranging from 1 = disagree strongly to 4 = agree strongly. All responses are summed and scaled from 0 to 100, which are then converted to an activation score using a scale provided by the developers of the PAM. | Cronbach’s $\alpha = .86$; construct and content validity supported in a population of patients undergoing BMT. | More desirable, reflecting greater activation.                                |
| **Depression**       |                                                                             |                                                                          |                                                                                         |                                                                             |
| Profile of Mood States (POMS) – Depression subscale | Fifteen-item measure indicative of depressed mood. Respondents rate the degree to which the adjective in each item is descriptive of their mood in the past week. | Five-point Likert scale ranging from 0 = not at all to 4 = extremely. T score with mean = 50; SD = 10 is derived. | Cronbach’s $\alpha = .95$; good convergent validity with other measures of depressed mood. | Less desirable, indicating more depressed mood.                               |
| **Anxiety**          |                                                                             |                                                                          |                                                                                         |                                                                             |
| State Trait Anxiety Inventory (STAI) | Forty-item measure that assesses State Anxiety (transitory state of tension, nervousness, or worry within a specific situation or context) and Trait Anxiety (tendency to perceive situations as threatening). | Four-point Likert scale ranging from 1 = not at all to 4 = very much so. Two 20-item scales: State Anxiety and Trait Anxiety. T score with mean = 50; SD = 10 is derived. | Cronbach’s $\alpha = .86$ to .95. Test-retest reliability = .31 to .86. Good convergent validity with other measures of anxiety and divergent validity from nonanxiety measures. | Less desirable, reflecting more anxiety.                                     |
| **Distress**         |                                                                             |                                                                          |                                                                                         |                                                                             |
| Profile of Mood States-2 (POMS-2)-Total | Sixty-five-item measure indicative of global distress or “Total Mood Disturbance” and six subscale scores: Fatigue, Vigor, Tension-Anxiety, Depression, Anger-Hostility, and Confusion. | Five-point Likert scale ranging from 0 = not at all to 4 = extremely with which respondents rate the degree to which the adjective in each item is descriptive of them in the past week. Total Mood Disturbance score is derived by summing all subscales but subtracting Vigor and converting it to a T score (mean, 50; SD, 10). | Cronbach’s $\alpha = .63$ to .96. Test-retest reliability = .61 to .69. Good concurrent validity. Factor structure confirmed by multiple studies. | Less desirable, reflecting more HCT-related distress.                        |

(Continued on following page)
Descriptive statistics were also calculated for utilization data and each PRO. Tertiles on the basis of frequency of total minutes of utilization were derived as follows: low (<7 minutes: 30th percentile), intermediate (7 to 55.5 minutes: 30th to 65th percentile), and high (>56 minutes: >65th percentile; Fig 1). Missing data (individual unanswered items) within the standardized measures were imputed using individualized mean substitutions within each measure. Repeated measures analysis of variance was used to determine change in PROs over time. At each time point, analysis of covariance (ANCOVA) was used to examine effects of utilization group on patient activation while accounting for variance as the result of age. Pearson correlations were used to determine the significance of association among demographic data (age, education), medical variables (length of hospital stay, cell dose), and PROs.

**Qualitative data.** Semistructured interviews were performed weekly during the participant’s inpatient stay to assess their qualitative interaction with BMT Roadmap, and at days 30 and 100 post-transplant, as previously described. Weekly interviews were conducted to check in with patients given the feasibility nature of this study, particularly to resolve any technical difficulties, but also to mitigate problems and repair them in real time. Briefly, all qualitative interviews were audio-recorded with permission, de-identified, professionally transcribed (Babbletype, Philadelphia, PA), and entered and coded in NVivo Pro 11. Transcriptions were reviewed and coded by a minimum of two research assistants until consensus was achieved. To ensure the quality and robustness of our findings, we performed interobserver reliability analysis on 10% of the coded interviews and demonstrated excellent reliability (κ = 0.96). A qualitative constant comparison of the data was conducted using a consistent set of codes (deductive approach). The coding structure was refined through iterative cycles of coding and data collection, and new emerging codes were also included (inductive approach).

# RESULTS

## Demographic Data

Twenty HCT patients undergoing first-time allogeneic HCT enrolled in the study between January and June 2016. All patients approached for the study enrolled and provided consent; no one declined. As shown in Table 2, the mean age of participants was 53 years (range, 27 to 71 years). The sample was predominantly male (n = 15), white (n = 18), and most participants had at least a high school diploma or higher education (n = 16). The indication for HCT was malignancy (n = 20). The majority of patients had an intermediate- to high-risk HCT comorbidity index (n = 14) and received an unrelated donor HCT (n = 11) from peripheral blood stem cell donors (n = 14).

---

**Table 1. Patient-Reported Outcomes Measured at Baseline, Discharge, and Day 100 (Continued)**

| PRO Description | Scoring | Psychometric Properties | High Scores |
|------------------|---------|-------------------------|-------------|
| Twenty-two–item scale that assesses subjective responses to acute traumatic events such as HCT. Total score indicates subjective stress made up of subsets of symptoms of intrusion, avoidance, and hyperarousal. | Cronbach’s α = .96. | Less desirable, reflecting more HCT-related distress. |
| Twenty-three-item measure that assesses distress specific to cancer and its treatment. Subscales: Uncertainty, family strains, medical demands, finances, identity, health burden. | Cronbach’s α = .92 to .94 in four cohorts of HCT patients. | Less desirable, reflecting more cancer-related distress. |

Abbreviations: HCT, hematopoietic cell transplantation; PRO, patient-reported outcome; SD, standard deviation.
The mean hospital stay for all study participants was 23.3 days (range, 17 to 37 days), and they had access to BMT Roadmap for a mean of 21.3 days (range, 15 to 37 days). The total time spent on BMT Roadmap ranged from 0 to 139 minutes per patient, with a mean of 55 minutes (standard deviation [SD], 47.6 minutes). Participants logged in at least once per day for a mean of 7.6 days (SD, 6.3 days). Participants spent the majority of their time in the laboratory module, followed by phases of care and medications. The least used module was the discharge checklist (Table 3).

**PRO Measures**

Eleven participants completed all of the PROs at each time point. Four patients did not complete baseline PROs as the result of technical error; two patients declined to complete the day 30 and day 100 PROs; and three patients died after discharge and did not complete day 100 PROs.

**Perceived Usefulness and Perceived Ease of Use**

Both Perceived Usefulness and Perceived Ease of Use showed high internal consistency (Cronbach’s alpha = 0.98). Perceived Usefulness and Perceived Ease of Use scores were in the intermediate range and did not change significantly from baseline to discharge to day 100 (Table 4).

**Patient Activation Measure**

Mean Patient Activation Measure (PAM) scores increased over the three time points (Table 4). At day 100, activation was inversely related to length of stay, ie, the more days spent as an inpatient, the lower the PAM score ($r = -0.52, P = .05$). The percent of the sample who scored
at PAM level 4, the highest level of activation, was 33.3% at baseline, 62.5% at discharge, and 57.1% at day 100. Among the 11 participants who completed the PAM at all three time points, repeated measures analysis of variance showed that activation significantly increased over time, with scores of 67.6 (SD, 16.65) at baseline, 72.8 (SD, 13.62) at discharge, and 77.7 (SD, 19.85) at day 100 ($F = 5.64, P = .04$).

Interestingly, we found that PAM scores were not linearly related to the total time BMT Roadmap was used. We then explored activation stratified by tertiles of total minutes of use. At discharge and day 100, the intermediate users showed a trend toward increased activation versus the lowest and highest users ($F = 3.52, P = .06$ and $F = 3.62, P = .06$, respectively), suggesting a quadratic or nonlinear relationship between the PAM and minutes of use.

As a result of the potential confounding effect of patient age on use of mobile technology, we then compared activation levels of intermediate users compared with all others, controlling for age in separate ANCOVAs at each time point. ANCOVAs revealed that at day 100, intermediate users were significantly more activated than low and high users, with mean activation scores of 99.8, 67.7, and 73.5, respectively ($F[2,10] = 5.29, P = .03$; partial $\eta^2 = 0.51$).

Table 2. Demographic Data and Medical Variables

| Variable                        | No. (%)          |
|---------------------------------|------------------|
| Mean age in years ± SD, range   | 52.65 ± 12.76, 27-71 |
| Sex                             |                  |
| Female                          | 5 (25)           |
| Male                            | 15 (75)          |
| Race/ethnicity                  |                  |
| White, non-Hispanic             | 18 (90)          |
| Black or African American       | 1 (5)            |
| Hispanic or Latin               | 1 (5)            |
| Education                       |                  |
| High school diploma or GED      | 6 (30)           |
| Some college or trade school    | 4 (20)           |
| Bachelor’s degree               | 2 (10)           |
| Graduate degree                 | 4 (20)           |
| Missing                         | 4 (20)           |
| Medical variables               |                  |
| Mean cell dose (x 10^6 CD34+ cells/kg) ± SD, range | 4.82 ± 2.42, 1.3-8.4 |
| Mean length of stay in days ± SD, range | 23.3 ± 5.00, 17-37 |
| Indication for HCT              |                  |
| Leukemia                        | 10 (50)          |
| Lymphoma                        | 4 (20)           |
| MDS                             | 5 (25)           |
| Multiple myeloma                | 1 (5)            |
| Donor                           |                  |
| Unrelated                       | 9 (45)           |
| Related                         | 11 (55)          |
| Comorbidity index               |                  |
| Low                             | 6 (30)           |
| Intermediate                    | 6 (30)           |
| High                            | 8 (40)           |
| Cell source                     |                  |
| PBSC                            | 14 (70)          |
| BM                              | 6 (30)           |
| HLA matched                     |                  |
| No                              | 1 (5)            |
| Yes                             | 19 (95)          |

Abbreviations: BM, bone marrow; GED, general equivalency diploma; HCT, hematopoietic cell transplantation; MDS, myelodysplastic syndrome; PBSC, peripheral blood stem cell; SD, standard deviation.

Mental Health PROs

Measures of depression (Profile of Mood States-Depression), trait and state anxiety (State Trait Anxiety Inventory), global distress (Profile of Mood States-Total), HCT-related distress (Impact of Events Scale-Revised), and Cancer and Treatment Distress were assessed to determine the effects of potential confounders on utilization and/or activation. We found that use was not significantly correlated with any of the mental health measures at any of the time points, suggesting that these variables did not confound utilization nor did utilization affect the mental health variables. However, the measures themselves were intercorrelated (Table 5). Notably, at baseline and discharge, depression correlated positively with state anxiety ($r = 0.71, P = .001$ and $r = 0.81, P = .01$, respectively), trait anxiety ($r = 0.78, P = .001$ and $r = 0.71, P = .01$, respectively), global distress ($r = 0.80, P = .001$ and $r = 0.63, P = .01$, respectively), and cancer-related distress ($r = 0.68, P = .01$ and $r = 0.61, P = .05$, respectively). By day 100, these relationships were attenuated, such that depression was associated to a significant
degree only with state anxiety and global distress (Table 5).

Activation was not associated with any of the mental health PROs at baseline or day 100 (ie, the two time points that represent time periods of no BMT Roadmap use). Interestingly, at discharge, activation correlated significantly and negatively with depression ($r = -0.59$, $P = .04$), trait anxiety ($r = -0.52$, $P = .05$), and state anxiety ($r = -0.52$, $P = .05$), suggesting that greater activation was associated with less depression and anxiety.

Depression and HCT-related distress (Impact of Event Scale-Revised) decreased significantly from baseline to discharge to day 100 post-HCT ($F = 7.83$, $P = .01$ and $F = 5.36$, $P = .02$, respectively). Similar trends were observed for state anxiety ($F = 3.59$, $P = .08$) and cancer-related distress ($F = 4.26$, $P = .07$).

Age, length of stay, and cell dose were not correlated with any mental health PROs at any time point. However, more educated patients showed more state anxiety at baseline and discharge ($r = 0.62$, $P = .01$ and $r = 0.54$, $P = .03$, respectively). In addition, at discharge, the patients who were more educated were more depressed ($r = 0.62$, $P = .01$) and exhibited a trend toward more overall emotional distress (Profile of Mood States-Total: $r = 0.47$, $P = .07$). By day 100, education was not correlated with any of the mental health PROs.

Integration of Quantitative PROs With Qualitative Findings

Participants were engaged in weekly semistructured interviews (Data Supplement). The five themes that emerged from weekly semistructured interviews in adult HCT patients were consistent with our prior findings in caregivers of pediatric HCT patients, which included the following: (1) emotional impact of the HCT process itself; (2) critical importance of communication among patients, caregivers, and providers; (3) ways in which BMT Roadmap was helpful in the inpatient setting; (4) suggestions for improvement of BMT Roadmap; and (5) other strategies for organization and management of complex health care needs that could be incorporated into BMT Roadmap.17 We provide a summary of representative qualitative data from adult HCT patients that are integrated with each PRO (Data Supplement).

DISCUSSION

There is a growing expectation that safe health care across the continuum must be organized using patient-centered systems.30 To achieve this, an integrated, multidisciplinary approach is needed to facilitate patient communication, collaboration, and efficiency.31 On the basis of user-centered design techniques, our multidisciplinary team developed a novel health IT tool for HCT patients to use during their hospital admission.12,14 We examined the views and perspectives of adult HCT recipients interacting with BMT Roadmap through qualitative interviews and quantitative PROs. To our knowledge, this is the first report of adult HCT patients interacting with a personalized health IT tool throughout their transplantation admission.

A central finding of our work was that patient activation increased across time (ie, baseline, discharge, and day 100). Importantly, increased activation at discharge was shown to be associated with reduced depression and anxiety. This suggests that activation may be a useful PRO measure for future HCT studies, as described in earlier studies in the pediatric HCT setting.12,33 Among adult HCT recipients, the burden of unmet mental health needs is high.34 Studies have shown that depression is associated with nonadherence to the post-HCT regimen, increased hospital length of stay, greater mortality, and increased suicidal ideation.35,36 Accordingly, efforts to provide patients with an interactive health IT avenue of communication with providers may

---

*Table 3. BMT Roadmap Use*

| Type of Use                    | Mean (SD)     | Range   |
|-------------------------------|---------------|---------|
| General use                   |               |         |
| Total time used (minutes)     | 55.0 (47.6)   | 0.0-138.8|
| Days between first and last login, inclusive | 14.5 (8.3)   | 1.0-28.0 |
| Days user logged in at least once | 7.6 (6.3)   | 1.0-22.0 |
| Module use (minutes)          |               |         |
| Laboratory results            | 13.5 (12.5)   | 0.0-44.5 |
| Phases of care                | 10.3 (9.3)    | 0.0-32.7 |
| Medications                   | 7.9 (7.9)     | 0.0-26.5 |
| Health care provider directory| 5.4 (5.3)     | 0.0-16.2 |
| Interactive discharge checklist| 0.7 (1.4)    | 0.0-5.2  |

Abbreviations: BMT, blood and marrow transplantation; SD, standard deviation.
improve activation as well as affect mental health variables.

Intriguingly, in our study, activation was not linearly related to minutes of use of the tool; patients who used the tool more were not necessarily more activated. Instead, we found that intermediate users had the highest levels of activation versus either low or high users. Although it is difficult to draw any specific conclusions from this finding given our nonrandomized data and small sample size, it suggests that there may be a sweet spot in terms of information utilization. It is possible that the tool was not effectively tailored for low or high users. For example, high users may have required even more information related to their health care. BMT Roadmap may not have adequately provided the information they needed to help them adopt new health behaviors, become more goal oriented, or display positive emotions. We were encouraged that participants were willing to complete PROs on the BMT Roadmap platform and share their experiences through qualitative interviews, despite being an older population with intermediate to high HCT comorbidity index.29 Accordingly, tailored information delivery according to PRO output may improve usefulness and usability of health IT tools and should be examined in future studies.37

Our preliminary findings reported herein are encouraging and provide a framework for future work using larger, more heterogeneous patient populations. A limitation of our study was related to technological barriers that participants experienced. These barriers, primarily related to logging on to the secure wireless network or being timed out and having to relog on to the program, are well-reported challenges.37 These barriers are likely to be overcome in future iterations of the IT tool, but will certainly need to be taken into account when other tools are developed. In part, these technical limitations are related to additional security enforced to protect patient privacy. Nonetheless, the strengths of this study include its longitudinal nature from admission through day 100, our rigorous methodology to evaluate patient views and perspectives with repeated qualitative assessments,17 and collection of well-validated PROs at three time points across the acute HCT trajectory. In contrast to five other early adopters of acute inpatient portals,37 our participants used BMT Roadmap for a longer hospital course and were followed prospectively with qualitative and quantitative PROs for > 100 days. In this study, patients had access to BMT Roadmap for a mean of 21.3 hospital days, which is longer than the duration of use described in other centers with inpatient

Table 4. Patient-Reported Outcome Measures

| Measure                          | No. of Patients | Mean (SD)     | Range |
|---------------------------------|-----------------|---------------|-------|
| Perceived Usefulness*           |                 |               |       |
| Baseline                        | 15              | 18.72 (9.78)  | 6-42  |
| Discharge                       | 17              | 18.18 (12.60) | 6-42  |
| Day 100                         | 14              | 19.38 (13.20) | 6-42  |
| Perceived Ease of Use*          |                 |               |       |
| Baseline                        | 15              | 12.06 (6.48)  | 6-27  |
| Discharge                       | 17              | 13.78 (12.72) | 6-42  |
| Day 100                         | 14              | 17.22 (12.66) | 6-42  |
| Patient Activation Measure (PAM)* |                 |               |       |
| Baseline                        | 15              | 64.93 (15.01) | 48.9-100.0 |
| Discharge                       | 16              | 72.13 (11.76) | 51.0-90.7 |
| Day 100                         | 14              | 77.53 (18.90) | 13.7-100.0 |
| Depression (POMS-D)*            |                 |               |       |
| Baseline                        | 15              | 45.11 (5.87)  | 40-62 |
| Discharge                       | 16              | 41.88 (2.91)  | 40-51 |
| Day 100                         | 14              | 41.78 (3.07)  | 40-50 |
| Anxiety-Trait (STAI-T)*         |                 |               |       |
| Baseline                        | 19              | 0.03 (1.14)   | −1.45 to 2.95 |
| Discharge                       | 17              | −0.23 (1.01)  | −1.56 to 1.48 |
| Day 100                         | 14              | −0.47 (1.06)  | −1.56 to 2.39 |
| Anxiety-State (STAI-S)*         |                 |               |       |
| Baseline                        | 19              | 0.07 (1.18)   | −1.4 to 3.34 |
| Discharge                       | 17              | −0.48 (0.87)  | −1.42 to 1.01 |
| Day 100                         | 14              | −0.63 (1.06)  | −1.52 to 1.40 |
| General distress (POMS-Total)*  |                 |               |       |
| Baseline                        | 19              | 48.79 (10.61) | 36-74 |
| Discharge                       | 17              | 45.59 (6.66)  | 36-56 |
| Day 100                         | 14              | 43.71 (6.41)  | 35-56 |
| HCT-related distress (IES-R)*   |                 |               |       |
| Baseline                        | 14              | 41.43 (13.39) | 26-65 |
| Discharge                       | 15              | 32.13 (7.42)  | 22-50 |
| Day 100                         | 14              | 28.85 (5.14)  | 22-37 |
| Cancer-related distress (CTXD)* |                 |               |       |
| Baseline                        | 15              | 1.08 (0.49)   | 0.32-1.82 |
| Discharge                       | 16              | 0.73 (0.50)   | 0.07-1.74 |
| Day 100                         | 14              | 0.59 (0.50)   | 0.04-1.82 |

Abbreviations: CTXD, Cancer and Treatment Distress; HCT, hematopoietic cell transplantation; IES-R, Impact of Event Scale-Revised; POMS, Profile of Mood States; POMS-D, Profile of Mood States Depression subscales; SD, standard deviation; STAI, State Trait Anxiety Inventory.

*Higher score is more desirable.
†Lower score is more desirable.
portals, such as Brigham and Women’s Hospital (Patient-Centered Toolkit), New York Hospital Presbyterian (myNYP.org), Ohio State University Wexner Medical Center (MyChart Bedside), El Camino Hospital Family Medical Officer (iFMO), and Northwestern Memorial Hospital. This suggests that further inquiry into the benefits of developing department- or disease-specific tools may be beneficial to patients. Such tools may also serve to improve their education and encourage involvement in their own care. Interpretation of our findings herein are further discussed in the Data Supplement.

To our knowledge, no other study has followed a cancer population for this length of time (ie, daily inpatient use during intense HCT therapy), while assessing the utility of a mobile IT application through both quantitative and qualitative PROs to help support the inpatient journey. We have an ongoing study assessing the impact of BMT Roadmap on caregivers of adult HCT patients. Our findings collectively indicate that it is critical to understand user views and perspectives in the design and development of such tools, which we did throughout the design and implementation of this project. Our key end users included pediatric patients and their caregivers (eg, parents, grandparents), as well as adult patients and their caregivers (eg, spouses, adult children). In addition, a collaborative and multidisciplinary team with input from providers, health informaticists, data scientists, computer scientists, engineers, and health communication scientists was critical in the design, implementation,

| Time Point | Activation | Depression | Trait Anxiety | State Anxiety | Global Distress | HCT-Related Distress | Cancer-Related Distress |
|------------|------------|------------|---------------|---------------|-----------------|----------------------|-------------------------|
| Baseline*  | Activation | −0.14      | −0.50         | −0.50         | −0.34           | −0.15                | −0.35                   |
|            | Depression | 0.78†      | 0.71†         | 0.80†         | 0.01            | 0.68†                |                         |
|            | Trait anxiety | 0.90†    | 0.88†         | 0.06          | 0.71†           |                      |                         |
|            | State anxiety | 0.85†    | 0.06          | 0.69†         |                 |                      |                         |
|            | Global distress |          | 0.19         | 0.76†         |                 |                      |                         |
|            | HCT-related distress |          |              |               |                 | 0.51                 |                         |

Discharge‡

| Time Point | Activation | Depression | Trait Anxiety | State Anxiety | Global Distress | HCT-Related Distress | Cancer-Related Distress |
|------------|------------|------------|---------------|---------------|-----------------|----------------------|-------------------------|
| Baseline*  | Activation | −0.59‖    | −0.50‖        | −0.52‖        | −0.46           | −0.17                | −0.23                   |
|            | Depression | 0.71†     | 0.81†         | 0.63†         | 0.12            | 0.61‖                |                         |
|            | Trait anxiety | 0.94†    | 0.66†         | 0.39          | 0.72†           |                      |                         |
|            | State anxiety | 0.82†    | 0.31          | 0.66†         |                 |                      |                         |
|            | Global distress |          | 0.30         | 0.59‖         |                 |                      |                         |
|            | HCT-related distress |          |              |               |                 | 0.39                 |                         |

Day 100¶

| Time Point | Activation | Depression | Trait Anxiety | State Anxiety | Global Distress | HCT-Related Distress | Cancer-Related Distress |
|------------|------------|------------|---------------|---------------|-----------------|----------------------|-------------------------|
| Baseline*  | Activation | −0.22      | −0.22         | −0.23         | −0.39           | −0.10                | −0.26                   |
|            | Depression | 0.46       | 0.82†         | 0.78†         | 0.33            | 0.39                 |                         |
|            | Trait anxiety | 0.84†    | 0.73†         | 0.65†         | 0.78†           |                      |                         |
|            | State anxiety | 0.88†    | 0.63‖         | 0.69†         |                 |                      |                         |
|            | Global distress |          | 0.45         | 0.46          |                 |                      |                         |
|            | HCT-related distress |          |              |               |                 | 0.76†                |                         |

Abbreviation: HCT, hematopoietic cell transplantation.

* n = 15-19
† P = .001
‡ P = .01
§ n = 16-17
‖ P = .05
¶ n = 14

Table 5. Intercorrelation Matrix of Patient-Reported Outcomes Over Time
and evaluation of BMT Roadmap. Nonetheless, we recognize the major limitations of our study, which include the nonrandomized, single-center design; small homogeneous sample; and technical barriers. However, given the severely ill nature of HCT patients, follow-up was actually fairly complete and overall retention in the study was high.

In conclusion, given the promising results reported in this study, our next steps include further iterations of the tool itself, focusing on increased ease of use and dynamism, extending use of the tool to outpatients, as well as conducting a randomized trial to assess whether the BMT Roadmap versus standard inpatient teaching is a primary driver of improved patient activation.

DOI: https://doi.org/10.1200/CCI.17.00110
Published online on ascopubs.org/journal/cc on January 11, 2018.

AUTHOR CONTRIBUTIONS
Conception and design: Larry An, David A. Hanauer, Sung Won Choi
Provision of study material or patients: Lyndsey Runaas, Tracey Churay, John Magenau, Sung Won Choi
Collection and assembly of data: Lyndsey Runaas, Flora Hoodin, Anna Munaco, Alex Fauer, Roshun Sankaran, Tracey Churay, Saara Mohammed, Sajjad Seyedsalehi, Grant Chappell, Leah McDiarmid, Kristina Brookshire, Casiana Warfield, Michelle Byrd, Sharon Kaziunas, Molly Maher, Amy Cohn, Sung Won Choi
Data analysis and interpretation: Lyndsey Runaas, Flora Hoodin, Anna Munaco, Alex Fauer, Roshun Sankaran, Tracey Churay, Sajjad Seyedsalehi, Noelle Carozzi, Michael D. Fetters, Leah McDiarmid, Kristina Brookshire, Casiana Warfield, Michelle Byrd, David A. Hanauer, Sung Won Choi
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Lyndsey Runaas
No relationship to disclose
Flora Hoodin
No relationship to disclose
Anna Munaco
Employment: Envision Medical Group (I)
Expert Testimony: Envision Medical Group (I)

Alex Fauer
No relationship to disclose
Roshun Sankaran
No relationship to disclose
Tracey Churay
No relationship to disclose
Saara Mohammed
No relationship to disclose

Sajjad Seyedsalehi
No relationship to disclose
Grant Chappell
No relationship to disclose
Noelle Carozzi
Consulting or Advisory Role: Teva

Michael D. Fetters
Honoraria: Medical Cyberworlds
Other Relationship: Medical Cyberworlds

Rachel Kenter
No relationship to disclose
Leah McDiarmid
No relationship to disclose
Kristina Brookshire
No relationship to disclose
Casiana Warfield
No relationship to disclose
Michelle Byrd
No relationship to disclose
Sharon Kaziunas
No relationship to disclose
Molly Maher
No relationship to disclose

Lawrence An
No relationship to disclose
John Magenau
No relationship to disclose

Lawrence An
No relationship to disclose

Amy Cohn
No relationship to disclose
David A. Hanauer
No relationship to disclose
Sung Won Choi
No relationship to disclose

ACKNOWLEDGMENT
We thank the patients and families who participated in this clinical research study.
Affiliations
Lyndsey Runaas, Flora Hoodin, Tracey Churay, Saara Mohammed, Sajjad Seyedsalehi, Grant Chappell, Noelle Carlozzi, Michael D. Fetters, Sharon Kaziunas, Molly Maher, John Magenau, Larry An, David A. Hanauer, and Sung Won Choi, Michigan Medicine; Anna Munaco, Alex Fauer, Roshun Sankaran, and Amy Cohn, University of Michigan College of Engineering, Ann Arbor; and Flora Hoodin, Rachel Kentor, Leah McDiarmid, Kristina Brookshire, Casiana Warfield, and Michelle Byrd, Eastern Michigan University, Ypsilanti, MI

Support
Supported by the Agency for Healthcare Research and Quality (R21HS23613), Fostering Innovations Grant, and Gracie Leukemia Grant.

Prior Presentation
Presented at the Annual Tandem Meeting, Orlando, FL, February 2017 and the Academy Health Annual Research Meeting, New Orleans, LA, June 2017.

REFERENCES
1. Copelan EA: Hematopoietic stem-cell transplantation. N Engl J Med 354:1813-1826, 2006
2. Pasquini MC, Wang Z: Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2013. http://www.cibmtr.org
3. Gemmill R, Cooke L, Williams AC, et al: Informal caregivers of hematopoietic cell transplant patients: A review and recommendations for interventions and research. Cancer Nurs 34:E13-E21, 2011
4. Cooke L, Grant M, Gemmill R: Discharge needs of allogeneic transplantation recipients. Clin J Oncol Nurs 16:E142-E149, 2012
5. Applebaum AJ, Bevans M, Son T, et al: A scoping review of caregiver burden during allogeneic HSCT: Lessons learned and future directions. Bone Marrow Transplant 51:1416-1422, 2016
6. Bevans M, Sternberg EM: Caregiving burden, stress, and health effects among family caregivers of adult cancer patients. JAMA 307:398-403, 2012
7. Van Der Wees PJ, Nijhuis-Van Der Sanden MW, Ayanian JZ, et al: Integrating the use of patient-reported outcomes for both clinical practice and performance measurement: Views of experts from 3 countries. Milbank Q 92:754-775, 2014
8. Lavallee DC, Chenok KE, Love RM, et al: Incorporating patient-reported outcomes into health care to engage patients and enhance care. Health Aff (Millwood) 35:575-582, 2016
9. Woollen J, Prey J, Wilcox L, et al: Patient experiences using an inpatient personal health record. Appl Clin Inform 7:446-460, 2016
10. Masterson Creber R, Prey J, Ryan B, et al: Engaging hospitalized patients in clinical care: Study protocol for a pragmatic randomized controlled trial. Contemp Clin Trials 47:165-171, 2016
11. Kaziunas E, Buyuktur A, Jones J, et al: Transition and Reflection in the Use of Health Information: The Case of Pediatric Bone Marrow Transplant Caregivers. Proceedings of the ACM2015 Conference on Computer Supported Cooperative Work (CSCW ‘15). Vancouver, British Columbia, Canada.
12. Kaziunas E, Hanauer DA, Ackerman MS, et al: Identifying unmet informational needs in the inpatient setting to increase patient and caregiver engagement in the context of pediatric hematopoietic stem cell transplantation. J Am Med Inform Assoc 23:94-104, 2016
13. Maher M, Kaziunas E, Ackerman M, et al: User-centered design groups to engage patients and caregivers with a personalized health information technology tool. Biol Blood Marrow Transplant 22:349-358, 2016
14. Maher M, Hanauer DA, Kaziunas E, et al: A novel health information technology communication system to increase caregiver activation in the context of hospital-based pediatric hematopoietic cell transplantation: A pilot study. JMIR Res Protoc 4:e119, 2015
15. Runaas L, Hoodin F, Kentor R, et al: User-centered design and development of a personalized mobile health application for adult HCT patients in the inpatient setting. Biol Blood Marrow Transplant 23:S419-S420, 2017
16. Runaas L, Bischoff E, Hoodin F, et al: A novel health informatics tool to improve caregiver activation: Findings from pediatric BMT in a hospital-based setting. Blood 128:2382, 2016
17. Runaas L, Hanauer D, Maher M, et al: BMT Roadmap: A user-centered design health information technology tool to promote patient-centered care in pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant 23:813-819, 2017
18. Fauer A, Runaas L, Bischoff E, et al: User-centered health information technology tool for blood and marrow transplant patients: A qualitative study. Presented at the Annual Research Meeting of Academy Health, New Orleans, LA, June 25-27, 2017.
19. Davis F: Perceived usefulness, perceived ease of use, and user acceptance of information technology. Manag Inf Syst Q 13:319-340, 1989
20. Hibbard JH, Mahoney ER, Stockard J, et al: Development and testing of a short form of the patient activation measure. Health Serv Res 40(6p1):1918-1930, 2005
21. Hibbard JH, Stockard J, Mahoney ER, et al: Development of the Patient Activation Measure (PAM): Conceptualizing and measuring activation in patients and consumers. Health Serv Res 39(4p1):1005-1026, 2004
22. McNair DM, Loor M, Droppelman LF. Profile of mood states. Educational and Industrial Testing Service, San Diego, CA. 1981.
23. Spielberger CD, Gorsuch RL, Lushene R, et al. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA. 1983.
24. Weiss DS, Marmar CR: Impact of Event Scale - Revised, in Wilson JP, Keane TM (eds): Assessing Psychological Trauma and Post Traumatic Stress Disorder: A Handbook for Practitioners. New York, NY, Guilford, 1997, pp 399-411
25. Syrjala KL, Yi JC, Langer SL: Psychometric properties of the Cancer and Treatment Distress (CTXD) measure in hematopoietic cell transplantation patients. Psychooncology 25:529-535, 2016
26. IBM SPSS Statistics for Windows: Version 24.0. Armonk, NY: IBM Corp. Released 2016.
27. Viera AJ, Garrett JM: Understanding interobserver agreement: The kappa statistic. Fam Med 37:360-363, 2005
28. Miles AB, Huberman AM. Qualitative Data Analysis, 2nd Ed. Sage Publications, Thousand Oaks, CA. 1994.
29. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005
30. Institute of Medicine. Delivering high-quality cancer care: Charting a new course for a system in crisis. The National Academy of Press, Washington, D.C. 2013.
31. Henriksen K, Battles JB, Marks ES, et al: (eds), Seamless Care: Safe Patient Transitions from Hospital to Home. in Advances in Patient Safety: From Research to Implementation, Vol. 1. Research Findings, Rockville, MD. 2005.
32. Pennarola BW, Rodday AM, Mayer DK, et al: Factors associated with parental activation in pediatric hematopoietic stem cell transplant. Med Care Res Rev 69:214-214, 2012
33. Pennarola BW, Rodday AM, Bingen K, et al: Changing factors associated with parent activation after pediatric hematopoietic stem cell transplant. Support Care Cancer 23:1997-2006, 2015
34. Barata A, Wood WA, Choi SW, et al: Unmet needs for psychosocial care in hematologic malignancies and hematopoietic cell transplant. Curr Hematol Malig Rep 11:280-287, 2016
35. Loberiza FR Jr, Rizzo JD, Bredeson CN, et al: Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 20:2118-2126, 2002
36. Prieto JM, Blanch J, Atala J, et al: Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol 20:1907-1917, 2002
37. Grossman LV, Choi SW, Collins S, et al: Implementation of acute care patient portals: Recommendations on utility and use from six early adopters. J Am Med Inform Assoc, 2017. Accepted